AI Opportunities for Life Sciences R&D - with Andrew Bolt of Deloitte

Today’s guest is Andrew Bolt, Partner at Deloitte. He joins Emerj CEO and Head of Research Daniel Faggella on today’s podcast to talk about challenges in R&D  for life sciences. While productivity has remained stagnant for the last 10-15 years, advances in AI-enhanced protein structure prediction are revolutionizing drug targeting and the very infrastructure of recruiting patients for clinical trials. Later, the two postulate on the ways AI can expedite regulatory compliance in pharmaceutical R&D in similar ways. Find out …

advances ai opportunities andrew ceo challenges daniel deloitte head joins life life sciences opportunities partner podcast prediction productivity protein protein structure protein structure prediction r&d research talk